Navegando por Palavras-chave "hormone replacement therapy"
Agora exibindo 1 - 6 de 6
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)Concentração de colágeno na pele facial de mulheres na pós-menopausa após tratamento com estradiol e genisteína tópicos: um estudo randomizado duplo cego(Universidade Federal de São Paulo (UNIFESP), 2016-07-29) Sampaio, Lidia Lima Aragao [UNIFESP]; Patriarca, Marisa Teresinha [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Objective: To compare the known effects of estrogen with genistein on the facial skin collagen of postmenopausal women without hormone therapy. Methods: This is a clinical, cross over trial with randomized and blinded convenience sample with estrogen and isoflavones, which 30 volunteer postmenopausal women were recruited to quantify facial collagen concentration before and after topical use of estrogen and isoflavones for 24 weeks. Results: The amount of both types I and III collagen increased at the end of both treatments, but estrogen was superior to the phytoestrogen, with statistical significance. Conclusion: Treatment with topical estrogen is superior to phytoestrogen, but both showed an increase in facial skin collagen, with statistical significance. What is not yet clear is whether prolonged topical use of such substances can cause systemic effects, thus, more research is needed to clarify this question.
- ItemSomente MetadadadosEvaluation of skin tolerability in patients on a 7-day regimen of a new matrix transdermal estradiol delivery system: An open-label study(Excerpta Medica Inc, 1997-07-01) Baracat, Edmund Chada [UNIFESP]; Yamada, Sérgio [UNIFESP]; Haidar, Mauro Abi [UNIFESP]; De Lima, Geraldo Rodrigues [UNIFESP]; Peloso, Ulisses; Benedictis, Eliana; Casoy, Julio; Universidade Federal de São Paulo (UNIFESP); WYETH AYERST RES; WYETH AYERST INTThe incidence and severity of local skin reactions, as well as the impact on the local bacteriologic profile, in a 7-day regimen of a matrix transdermal estradiol delivery system compared with placebo (a piece of adhesive tape for sensitive skin of approximately the same shape and area) were assessed in healthy postmenopausal Brazilian women in an open-label study. the matrix estradiol and placebo patches were applied to different sites of the abdominal area, worn for 7 consecutive days, and then replaced according to an established rotation schedule, until 5 weeks of treatment were completed. the rotation schedule was adopted to provide an assessment of skin reaction as related to (1) interval between two consecutive placements at the same application site; (2) number of repetitions; and (3) abdominal region (upper, middle, and lower). A skin reaction score was obtained at each site before the application of each patch, 80 minutes after patch removal, and 7 days after patch removal. Skin swabs were obtained for bacteriologic cultures immediately before patch application and immediately after patch removal. Twenty-seven women were enrolled and completed the study; 270 skin observations were made with the estradiol patch and 162 with placebo. Skin reactions 30 minutes after patch removal included erythema (23.7%), erythema with induration (4.1%), and erythema with induration and vesicles (1.1%). Seven days after patch removal, skin reactions had decreased to erythema (2.2%) and erythema with induration (0.4%); no erythema with induration and vesicles was seen. This reduction in incidence and severity was statistically significant. Thirty minutes after placebo removal, 2.5% of skin observations detected erythema; no erythema was observed 7 days later. No other severe reactions were observed, and no clinically significant alteration in skin flora was detected. the results of this study indicate an acceptable level of local skin responses to this 7-day estradiol patch application. in addition, 96.3% of patients rated the estradiol patch as good or very good in its acceptability.
- ItemAcesso aberto (Open Access)Histomorfometria da mama de ratas tratadas com estrogênio e/ou progestagênio(Associação Médica Brasileira, 2011-04-01) Torres, Sueli Maria Preda dos Santos; Simões, Ricardo Santos; Baracat, Maria Cândida Pinheiro [UNIFESP]; Gomes, Regina Célia Teixeira [UNIFESP]; Soares Júnior, José Maria [UNIFESP]; Carbonel, Adriana Aparecida Ferraz [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Centro Universitário Lusíada - UNILUS; Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)OBJECTIVE: To evaluate the breast histomorphometric changes in rats treated with estrogen and/or progestogen for a short period of time. METHODS: Forty oophorectomized rats were divided into four groups: GC, vehicle; GE, treated with estradiol benzoate (37.6 mg/animal); GP, treated with medroxyprogesterone acetate (11.2 mg/animal) and GEP, treated with estradiol benzoate (37.6 mg/animal) plus medroxyprogesterone acetate (11.28 mg/animal). In GE group, estradiol was administered subcutaneously for seven days; in GEP group, estradiol was administered once in a day for the first seven days and the progestogen over the next 23 days both subcutaneously. Twenty-four hours after the last hormone administration, the animals were killed upon deep anesthesia and the first inguinal breasts were removed, fixed in 10% formaldehyde and processed to be included in paraffin, with the sections being stained by hematoxylin-eosin. Morphology and the area occupied by mammary parenchyma were assessed, with the data undergoing analysis of variance followed by the Kruskal-Wallis test (p < 0.05). RESULTS: The control group breasts were found atrophic and, in GE and GEP group animals, typical alveoli with secretion inside are present; in progestogen-treated animals (GP), alveoli formed by large cells occupying almost the entire alveolar lumen are noted. Morphometric analysis showed a larger mammary parenchyma area in hormone-treated animals (GE = GP > GEP > GC; p < 0.05). CONCLUSION: Estradiol and progestogen had a proliferative effect on mammary parenchyma. However, prior estradiol administration changes the progestogen action on rat mammary tissue.
- ItemSomente MetadadadosOnset of estrogen replacement has a critical effect on synaptic density of CA1 hippocampus in ovariectomized adult rats(Lippincott Williams & Wilkins, 2003-09-01) Silva, I; Mello, LEAM; Freymuller, E.; Haidar, Mauro Abi [UNIFESP]; Baracat, E. C.; Universidade Federal de São Paulo (UNIFESP)Objectives: the aim of this study was to evaluate differences between estrogen replacement therapy initiated either 4 or 12 days after ovariectomy on the synaptic density of the hippocampal CA1 field in rats.Design: Female, adult, Wistar rats were ovariectomized bilaterally under ether anesthesia and divided among the following groups: 1) estrogen (conjugated equine estrogen 50 mug in 0.5 mL of propylene glycol, daily, p.o. gavage, for 60 days), starting 4 days after ovariectomy (n = 5); 2) propylene glycol (0.5 mL daily, p.o. gavage, for 60 days), starting 4 days after ovariectomy (n = 4); 3) estrogen (conjugated equine estrogen 50 mug in 0.5 mL of propylene glycol, daily, p.o. gavage, for 45 days), starting 12 days after ovariectomy (n = 3); 4) propylene glycol (0.5 mL daily, p.o. gavage, for 45 days), starting 12 days after ovariectomy (n = 3). At the end of the treatment, the rats were processed for electron microscopy and light analysis.Results: Synaptic density in all of the CA1 strata subjected to evaluation was significantly higher in animals in which estrogen replacement was initiated 4 days after ovariectomy as compared with controls. in contrast, initiation of treatment after a 12-day interval did not result in recovery of synaptic density in any of the CA1 strata and was significantly lower than that of the animals subjected to hormone replacement after a 4-day delay (P < 0.01).Conclusion: the delay for hormone replacement therapy might have critical implications for modulating synaptic density.
- ItemSomente MetadadadosA randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability(Parthenon Publishing Group, 2002-03-01) Baracat, E. C.; Barbosa, I. C.; Giordano, M. G.; Haidar, Mauro Abi [UNIFESP]; Marinho, R. M.; Menegocci, J. C.; Morais, K. M.; Tomaz, G.; Wehba, S.; Universidade Federal de São Paulo (UNIFESP); Universidade Federal da Bahia (UFBA); Universidade Federal do Rio de Janeiro (UFRJ); Fac Med Sci Minas Gerais; Pontifical Catholic Univ; Univ Fed Rio Grande Norte; Univ Fed Paraiba; Santa Casa MisericordiaObjective To compare the effects of continuous combined conjugated equine estrogens plus medroxyprogesterone acetate (CEE/MPA) with those of tibolone on symptom control, bleeding pattern, lipid profile and tolerability in postmenopausal women.Methods This was a randomized, open-label, parallel-group, multicenter study. Generally healthy postmenopausal women with an intact uterus and no contraindications to hormone replacement therapy (HRT) or tibolone were enrolled. Each subject was randomly assigned to receive CEE/MPA 0.625 mg-5.0 mg or tibolone 2.5 mg daily for 13 treatment cycles, each of 28 days.Results A total of 85 subjects were enrolled and received at least one dose of study medication, of which 76 (89.4%) subjects completed the study (n = 40, CEE/MPA; n = 363 tibolone). the incidence of postmenopausal symptoms decreased significantly over time in both treatment groups, compared with baseline, including significant decreases in the incidence of urogenital and sexual health symptoms. Significant differences in symptom control (other than hot flushes) were observed between treatment groups in a few different cycles for different symptoms, but no consistent or clinically significant trends were observed. No statistically significant differences in the incidence of bleeding were observed between treatment groups after cycle 4. Significant decreases in total cholesterol (5.6%) and low-density lipoprotein (LDL) cholesterol (7.5%) were observed at cycle 13, compared with baseline, in the CEE/MPA group, and significant decreases in high-density lipoprotein (HDL) cholesterol (8.5%) and triglycerides (13.7%) were observed at cycle 13, compared with baseline, in the tibolone group. Significant weight gain was observed at cycle 13 in the. tibolone group (3.05 kg), compared with the CEE/MPA group (0.96 kg). the incidences of adverse events were similar in both treatment groups.Conclusions Women treated with CEE/MPA or tibolone showed significant improvement of postmenopausal symptoms, including urogenital and sexual health symptoms, and had similar bleeding patterns after four cycles of therapy. CEE/MPA and tibolone each induced a different mix of changes in the lipid profile.
- ItemSomente MetadadadosSelective estrogen receptor modulators in chronic renal failure(Nature Publishing Group, 2003-06-01) Weisinger, Jose R; Heilberg, Ita Pfeferman [UNIFESP]; Hernandez, Eddy; Carlini, Raul; Bellorin-Font, Ezequiel; Univ Munich; Universidade Federal de São Paulo (UNIFESP); San Carlo Borromeo HospBackground. In addition to renal osteodystrophy, postmenopausal women on dialysis could be at risk of osteoporosis. Hormone replacement therapy (HRT) could have beneficial effects as well as potentially serious risks, especially in uremic women, due to the pharmacokinetics of estradiol in renal failure. Therapeutic alternatives, such as the selective estrogen receptor modulators (SERMs), have shown the benefits of estrogen on bone and serum lipid levels, without its adverse effects on the breast and endometrium, in nonuremic women.Methods. Recent data on the effect of the SERM raloxifene in bone and lipid metabolism in osteoporotic postmenopausal women on dialysis is reviewed. Since the estrogen receptor (ER) gene has been suggested as a candidate marker for osteoporosis, we investigated whether ER polymorphism could have predicted the BMD response to raloxifene.Results. Hemodialyzed women on raloxifene demonstrated increased trabecular bone mineral density (BMD) and decreased bone resorption markers. Similarly, LDL-cholesterol values dropped significantly. ER gene polymorphism analysis of baseline BMD parameters did not differ between PP/xx or Pp/Xx groups. Nevertheless, patients on raloxifene with PP/xx genotypes, but not those with Pp/Xx, showed a higher trabecular BMD after one year on treatment, suggesting that homozygous women for P or x alleles of the ER have a better BMD response to raloxifene.Conclusion. Raloxifene and, most likely, other SERMs, could represent a good alternative to HRT in postmenopausal uremic women.